Byotrol Overview

  • Founded
  • 2005
Founded
  • Status
  • Public
  • Employees
  • 34
Employees
  • Stock Symbol
  • BYOT
Stock Symbol
  • Investments
  • 5
  • Share Price
  • $0.07
  • (As of Friday Closing)

Byotrol General Information

Description

Byotrol PLC is a developer of consumer and professional antimicrobial technologies and products. It is engaged in the development, patenting and sale of products based on microbial technology. Its operations are in the United Kingdom and the United States of America. It operates in two reportable segments, being Professional (including Human Health, Animal Health, Facilities Management, and Food & Beverage), and Consumer (Including Household, Skin Care, and Pet Care). Its customers are based in the UK, North America, and the Rest of the World.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Other Commercial Services
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
LON
Primary Office
  • Building 303 (Ashton)
  • Thornton Science Park, Pool Lane, Ince
  • Chester CH2 4NU
  • England, United Kingdom
+44 01925 000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Byotrol Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.07 $0.07 $0.05 - $0.11 $31M 454M 586K

Byotrol Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2021 31-Mar-2021 FY 2020 31-Mar-2020 FY 2019 31-Mar-2019
EV 33,864 33,864 27,384 8,870
Revenue 14,634 14,634 7,643 7,428
EBITDA 1,965 1,965 926 1,236
Net Income 1,150 1,150 424 462
Total Assets 13,114 13,114 11,307 11,876
Total Debt 41 41 453 320
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Byotrol Patents

Byotrol Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3122051-A1 Anti-viral composition Pending 05-Dec-2018 000000000
GB-201819849-D0 Anti-viral composition Pending 05-Dec-2018 000000000
AU-2019394176-A1 Anti-viral composition Pending 05-Dec-2018 000000000
GB-2579600-A Anti-viral composition Pending 05-Dec-2018 000000000 0
EP-3890760-A1 Anti-viral composition Pending 05-Dec-2018 A61K36/03

Byotrol Executive Team (5)

Name Title Board Seat Contact Info
David Traynor Chief Executive Officer & Board Member
Nic Hellyer Chief Financial Officer & Board Member
You’re viewing 2 of 5 executive team members. Get the full list »

Byotrol Board Members (3)

Name Representing Role Since
00000 0000000 Byotrol Chief Executive Officer & Board Member 000 0000
0000 000000000 Byotrol Chairman & Board Member 000 0000
000 0000000 Byotrol Chief Financial Officer & Board Member 000 0000
To view Byotrol’s complete board members history, request access »

Byotrol Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Byotrol Investments & Acquisitions (5)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 0000 23-Aug-2018 0000000000 00.000 Specialty Retail 0000 0000
00000000000 17-Mar-2017 0000000000 000.00 Other Healthcare Technology Systems 00000 000
0000000 00000 09-Oct-2013 0000000000 00.000 Other Consumer Durables 0000 0000
00000000 04-Feb-2010 0000000000 00.000 Other Consumer Non-Durables
Byotrol Consumer Products 30-Jul-2007 Joint Venture Other Consumer Durables 0000 0000
To view Byotrol’s complete investments and acquisitions history, request access »

Byotrol Subsidiaries (1)

Company Name Industry Location Founded
00000000 000000000 Specialty Retail Sevenoaks, United Kingdom 0000
To view Byotrol’s complete subsidiaries history, request access »